Clinical trials: Gastroenteritis
Gastritis
To Evaluate Improvement Effect of Subjective Symptoms of Mucotra SR Tablet in Patients With Gastritis
This study aims to evaluate the improvement effect on subjective symptoms of gastritis and adverse events through patient self-assessment results (PRO) by conducting follow-up observations for patients with gastritis at 2 to 4…
- Trial name
- NCT06668506
- Where
- South Korea
- Volunteers
- 2,814 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Ulcerative Colitis, Crohn's Disease
A Phase I Study of Etrolizumab Followed by Open-Label Extension and Safety Monitoring in Pediatric Patients With Moderate to Severe Ulcerative Colitis or Moderate to Severe Crohn's Disease
This study will evaluate pharmacokinetics, pharmacodynamics and safety of etrolizumab in pediatric patients of 4 to <18 years of age with moderate to severe ulcerative colitis (UC) or with moderate to severe Crohn's disease (CD).
- Trial name
- FENNEL (NCT03478956)
- Testing
- Etrolizumab
- Where
- 5 sites in Belgium, Poland and 2 more
- Volunteers
- 24 people
- Sponsor
- Hoffmann-La Roche
Ulcerative Colitis
A Study of Pentasa in Patients With Ulcerative Colitis
Confirmation of safety profile of Pentasa slow release tablets 500 mg in patients with ulcerative colitis (UC).
- Trial name
- NCT01104753
- Where
- 30 sites in Czechia
- Volunteers
- 338 people
- Sponsor
- Ferring Pharmaceuticals
Gastritis
A Study of Compare the Pharmacokinetic, Pharmacodynamic and Safety/Tolerability Characteristics Following Multiple Oral Administration of AD-234, AD-2341, and AD-2342 in Healthy Adults
Primary endpoint of this study is to evaluate the pharmacokinetic and pharmacodynamic characteristics of AD-234, AD-2341, AD-2342 in healthy subjects.
- Trial name
- NCT07717775
- Testing
- AD-234, AD-2341, AD-2342
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Ulcerative Colitis, Inflammatory Bowel Disease
Study Evaluating rhIL-11 in Left-Sided Ulcerative Colitis
To explore the safety of orally delivered rhIL-11 in patients with mild to moderate left-sided ulcerative colitis. To explore the effects of orally administered rhIL-11 on pharmacogenomics in blood samples and in colonic biopsy…
- Trial name
- NCT00038922
- Testing
- rhIL-11
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Crohn's Disease
Certolizumab Pegol for Treatment of Adult Greek Patients With Moderate to Severe Crohn's Disease Who Failed Infliximab
An open-label multi-center single-cohort study to assess the safety and efficacy of certolizumab pegol for the treatment of signs and symptoms of active Crohn's disease in Greek patients who have previously responded to…
- Trial name
- NCT00307931
- Testing
- Certolizumab pegol
- Where
- 5 sites in Greece
- Volunteers
- 16 people
- Sponsor
- UCB Pharma
Crohn´s Disease
9 mg Budesonide Once Daily (OD) Versus 3 mg Budesonide Three Times Daily (TID) in Active Crohn's Disease
This study aims to evaluate the efficacy of 9 mg budesonide once daily (OD) versus 3 mg budesonide three-times daily (TID) for the induction of remission in Crohn's disease.
- Trial name
- NCT01086553
- Testing
- budesonide
- Where
- Germany
- Volunteers
- 471 people
- Sponsor
- Dr. Falk Pharma GmbH
Crohn's Disease
An Efficacy and Safety Study of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease
The purpose of this study is to see if Epanova™ is able to maintain the symptomatic remission in subjects with Crohn's Disease who are responding to steroid induction therapy.
- Trial name
- NCT00074542
- Testing
- Epanova™ (Omega-3 Free Fatty Acids)
- Where
- 31 sites in United States, Canada
- Volunteers
- 364 people
- Sponsor
- Tillotts Pharma AG
Complex Perianal Fistula, Crohn Disease
Safety and Efficacy of Adipose-Derived Stem Cells to Treat Complex Perianal Fistulas Patients With Crohn's Disease
The purpose of this study is to determine safety and efficacy of eASCs (expanded adult stem cells) for treatment of complex perianal fistulas in patients with Crohn's disease.
- Trial name
- FATT (NCT01378390)
- Testing
- Expanded autologous adipose-derived adult stem cells (eASCs)
- Where
- 12 sites in Austria, Netherlands and 1 more
- Volunteers
- 56 people
- Sponsor
- Tigenix S.A.U.
Crohn's Disease
Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine
The purpose of this study was intended to evaluate the long-term safety and effectiveness of adalimumab in participants with Crohn's disease (CD) who are treated as recommended in the product label.
- Trial name
- NCT01083680
- Volunteers
- 4,107 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Crohn's Disease
Semapimod for Treatment of Moderate to Severe Crohn's Disease 1 or 3 Days' Treatment Versus Placebo
Assessment of the number of days' treatment with semapimod necessary for efficacy, as measured by response rate to CNI-1493 as compared to placebo, in patients with moderate to severe Crohn's disease (CD).
- Trial name
- CD04 (NCT00739986)
- Testing
- Semapimod
- Where
- 28 sites in United States, Belgium and 3 more
- Volunteers
- 152 people
- Sponsor
- Ferring Pharmaceuticals
Crohn's Disease
A Study to Assess the Effectiveness of Second-Line Therapy of Upadacitinib and Risankizumab in Adult Participants With Crohn's Disease in a Real-World Setting
Crohn's disease (CD) is an incurable chronic inflammatory disorder of the gastrointestinal tract. This study will evaluate the second line effectiveness of upadacitinib and risankizumab in Crohn's Disease (CD) in a real-world…
- Trial name
- CROHNOS (NCT07073079)
- Where
- 25 sites in Italy
- Volunteers
- 250 people
- Sponsor
- AbbVie
Ulcerative Colitis
Etrasimod Dose-Ranging Versus Placebo as Induction Therapy Study in Adult Japanese Subjects With Moderately to Severely Active Ulcerative Colitis
The purpose of this Japan-only study is to assess the safety and efficacy of etrasimod at 2 doses in Japanese subjects with moderately to severely active ulcerative colitis (UC) when administered for 12 weeks.
- Trial name
- NCT05061446
- Testing
- Etrasimod
- Where
- 80 sites in Japan
- Volunteers
- 54 people
- Sponsor
- Pfizer
Ulcerative Colitis
(CB-01-02/04) Extension Study of Budesonide Multi-Matrix System (MMX) 6 mg in Maintenance Of Remission In Patients With Ulcerative Colitis.
Randomized, double-blind, comparative study versus placebo performed in patients from studies CB-01-02/01 (NCT00679432), CB-01-02/02 (NCT00679380), or CB-01-02/06 (NCT01100112) who achieved ulcerative colitis disease activity…
- Trial name
- NCT00801723
- Testing
- Budesonide MMX 6 mg Tablet
- Where
- 58 sites in United States, Canada
- Volunteers
- 123 people
- Sponsor
- Bausch Health Americas, Inc.
Crohn's Disease
Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease
This study will evaluate the efficacy and safety of adalimumab induction and maintenance treatment in subjects with moderately to severely active Crohn's disease in China.
- Trial name
- NCT02499783
- Testing
- adalimumab
- Volunteers
- 205 people
- Sponsor
- AbbVie
Healthy, Colitis, Ulcerative
A Study of JNJ-66525433 in Healthy Participants and Participants With Ulcerative Colitis
The purpose of this study is to evaluate safety and tolerability of JNJ 66525433 compared with placebo after administration of: 1) single ascending oral doses of JNJ 66525433 administered to healthy participants (Part 1), 2)…
- Trial name
- NCT04457960
- Testing
- JNJ-66525433
- Where
- Germany
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Infections, Rotavirus
Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix™ (Human Rotavirus Vaccine) in Indian Infants
This post marketing surveillance will evaluate reactogenicity and safety data of human rotavirus vaccine when administered to healthy infants according to the Prescribing Information in India.
- Trial name
- NCT00938327
- Testing
- Rotarix™
- Where
- 12 sites in India
- Volunteers
- 332 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Ulcerative Colitis
Mesalazine 4g Once Daily Versus 4g in Two Divided Doses in Active Ulcerative Colitis.
The purpose of this study was to demonstrate that mesalazine 4g orally per day once daily (QD) is non-inferior to the reference regimen, mesalazine 4g per day in two divided doses (BID) (2g x 2 per day), in patients with active…
- Trial name
- NCT00737789
- Testing
- Mesalazine slow-release granules, Mesalazine liquid enema
- Where
- 66 sites in Belgium, France and 2 more
- Volunteers
- 206 people
- Sponsor
- Ferring Pharmaceuticals
Ulcerative Colitis
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis
The primary purpose of this study was to determine the effect of vedolizumab induction treatment on clinical response at 6 weeks and to determine the effect of vedolizumab maintenance treatment on clinical remission at 52 weeks.
- Trial name
- GEMINI I (NCT00783718)
- Testing
- vedolizumab
- Where
- 105 sites in United States, Canada and 1 more
- Volunteers
- 895 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Acute Gastroenteritis
Efficacy and Safety of Probiotics in the Treatment of Acute Gastroenteritis in Children
Primary Objective: o To assess the efficacy of the probiotics in reducing the duration of diarrhea in children suffering from acute gastroenteritis.
- Trial name
- SABINA (NCT03539913)
- Testing
- Probiotic : Saccharomyces boulardii, Probiotic : Bacillus clausii
- Where
- 8 sites in Argentina
- Volunteers
- 317 people
- Sponsor
- Biocodex